Atara Biotherapeutics, Inc.
ATRA · XNASCIK 1604464fmd_14PEF5FYX3T7CSSPYASQ4MRXTXManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 54 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | 64 | 9 | 129 | 121 |
| Research and development | 57 | 81 | 167 | 216 | 245 | 282 | 273 | 225 | 151 | 37 |
| Gain on sale of real estate | – | – | – | – | 0 | 0 | 50 | 0 | – | – |
| Total operating expenses | 81 | 122 | 237 | 296 | 309 | 361 | 344 | – | – | – |
| Operating income | (81) | (122) | (237) | (296) | (309) | (340) | (281) | (276) | (83) | 36 |
| Interest expense | – | – | – | – | – | – | 0 | 5 | 5 | 4 |
| Other non-operating income (expense) | 2 | 2 | 6 | 5 | 2 | 0 | (1) | (0) | 1 | (0) |
| Income before taxes | (79) | (120) | (231) | (291) | (307) | (340) | (228) | (276) | (85) | 33 |
| Income tax expense | 0 | (0) | (0) | 0 | 0 | 0 | 0 | 0 | (0) | 0 |
| Net income from continuing operations | (79) | (119) | (231) | (291) | (307) | (340) | (228) | (276) | (85) | 33 |
| Net income | (79) | (119) | (231) | (291) | (307) | (340) | (228) | (276) | (85) | 33 |